Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 3/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134840 | 0.87 | PPARG (0.51) | PPARGCYP11B2AKR1B1FFAR1 | |
| SCHEMBL10135329 | 0.80 | PPARG (0.49) | PPARGRXRAPTGDR2PPARDFFAR1 | |
| SCHEMBL4556146 | 0.79 | PPARG (0.55) | PPARGCYP11B2 | |
| SCHEMBL4556065 | 0.78 | PPARG (0.51) | PPARGRXRATBXA2RAKR1B1 | |
| SCHEMBL4556264 | 0.77 | PPARG (0.50) | PPARGPTGDR2 | |
| SCHEMBL4556106 | 0.76 | PPARG (0.48) | PPARGRXRAPTGDR2AKR1B1 | |
| SCHEMBL4556253 | 0.76 | PPARG (0.48) | PPARGRXRAPTGDR2AKR1B1 | |
| SCHEMBL4556250 | 0.75 | PPARG (0.50) | PPARGCYP11B2RXRAPTGDR2PPARD | |
| SCHEMBL13940961 | 0.74 | PPARG (0.37) | PPARGRXRAPTGDR2AKR1B1 | |
| SCHEMBL10135257 | 0.74 | PPARG (0.51) | PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168656-B2 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | VANDERBILT UNIVERSITY (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090118290-A1 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | VANDERBILT UNIVERSITY | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118290-A1 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | AANAT, FABP2, SI | PPARG 9/4885CYP11B2 132/4885RXRA 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.